Healthcare is a very dynamic and diverse sector, fuelled by an ageing population coupled with an increasing prevalence of chronic conditions driving ever greater healthcare spending.

In biotechnology and pharmaceuticals, the landscape is evolving quickly. There is a revolution in immuno-oncology with new treatments emerging as widely-adopted therapies. Cell and gene therapies are on the cusp of providing long-term treatments for many acquired and hereditary diseases.

The team is multidisciplinary, with backgrounds in scientific research, strategic consultancy, accountancy and buy-side investment underpinned by academic backgrounds in life sciences. Panmure Gordon has been the sector’s most active adviser for fundraising in the market since 2016.

We work with companies across the sector including in:

  • Biotechnology
  • Pharmaceuticals
  • Medical technology
  • Care services
  • Animal health

Our dedicated team advises on all elements of fundraising for UK and international companies, attracting both UK and overseas investment including:

  • IPO
  • Secondary fundraising
  • M&A

a selection of client transactions

Diurnal Group plc


Joint broker, Nomad

£11 million

MaxCyte Inc

Secondary Offering

Financial Adviser, Nominated Adviser and Broker

£10 million

CareTech Holdings plc

Acquisition of Cambian Group plc

Joint Financial Adviser and Broker

£372 million

“CareTech has worked with Panmure Gordon for many years and they have advised us on numerous successful transactions. When contemplating transformational M&A, we wanted Panmure Gordon, our trusted adviser, at our side from the outset. The Panmure Gordon team delivered regulatory advice that was both precise and commercial, as well as clear and effective shareholder communication. The team are professional, proactive and committed to helping our business achieve its aims.”

Farouq Sheikh, Founder & Executive Chairman, CareTech

Freddy Crossley

Head of Healthcare